Saad B Omer1, Varun K Phadke2, Robert A Bednarczyk3, Allison T Chamberlain4, Jennifer L Brosseau4, Walter A Orenstein5. 1. Hubert Department of Global Health Department of Epidemiology, Rollins School of Public Health Department of Pediatrics Emory Vaccine Center, Emory University, Atlanta, Georgia. 2. Division of Infectious Diseases, School of Medicine. 3. Hubert Department of Global Health Emory Vaccine Center, Emory University, Atlanta, Georgia. 4. Department of Epidemiology, Rollins School of Public Health. 5. Hubert Department of Global Health Department of Pediatrics Emory Vaccine Center, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Statins have antiinflammatory effects that may impact vaccine-induced immune responses. We investigated the impact of statin therapy on influenza vaccine effectiveness (VE) against medically attended acute respiratory illness (MAARI). METHODS: We conducted a retrospective cohort study over nine influenza seasons using research databases of a large managed care organization in the United States. Influenza vaccination and statin prescription statuses of cohort members and MAARI cases were ascertained on a per-season basis. Incidence rate ratios (IRRs) of MAARI were estimated using Poisson regression and stratified by statin use. Using a ratio of ratios approach, we compared IRRs from periods during to IRRs from periods before influenza circulation and then used relative IRRs to compute VE. RESULTS: After adjustment for multiple prespecified covariates, the influenza VE against MAARI was lower among statin users than nonusers during periods of local (14.1% vs 22.9%; mean difference, 11.4%; 95% confidence interval [CI], -1.7% to 26.1%) and widespread (12.6% vs 26.2%; mean difference, 18.4%; 95% CI, 2.9%-36.2%) influenza circulation. CONCLUSIONS: In this study, statin therapy was associated with reduced influenza VE against MAARI. Since many cases of MAARI are not caused by influenza, studies of the impact of statins on influenza VE against laboratory-confirmed influenza are needed.
BACKGROUND: Statins have antiinflammatory effects that may impact vaccine-induced immune responses. We investigated the impact of statin therapy on influenza vaccine effectiveness (VE) against medically attended acute respiratory illness (MAARI). METHODS: We conducted a retrospective cohort study over nine influenza seasons using research databases of a large managed care organization in the United States. Influenza vaccination and statin prescription statuses of cohort members and MAARI cases were ascertained on a per-season basis. Incidence rate ratios (IRRs) of MAARI were estimated using Poisson regression and stratified by statin use. Using a ratio of ratios approach, we compared IRRs from periods during to IRRs from periods before influenza circulation and then used relative IRRs to compute VE. RESULTS: After adjustment for multiple prespecified covariates, the influenza VE against MAARI was lower among statin users than nonusers during periods of local (14.1% vs 22.9%; mean difference, 11.4%; 95% confidence interval [CI], -1.7% to 26.1%) and widespread (12.6% vs 26.2%; mean difference, 18.4%; 95% CI, 2.9%-36.2%) influenza circulation. CONCLUSIONS: In this study, statin therapy was associated with reduced influenza VE against MAARI. Since many cases of MAARI are not caused by influenza, studies of the impact of statins on influenza VE against laboratory-confirmed influenza are needed.
Authors: Eelko Hak; Erik Buskens; Gerrit A van Essen; Dinny H de Bakker; Diederick E Grobbee; Margot A J B Tacken; Ben A van Hout; Theo J M Verheij Journal: Arch Intern Med Date: 2005-02-14
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: Pui Y Lee; Philip O Scumpia; Joanne A Byars; Kindra M Kelly; Haoyang Zhuang; Jonathan S Shuster; Douglas W Theriaque; Mark S Segal; Westley H Reeves; Mark L Brantly Journal: Vaccine Date: 2006-01-09 Impact factor: 3.641
Authors: M Alan Brookhart; Amanda R Patrick; Colin Dormuth; Jerry Avorn; William Shrank; Suzanne M Cadarette; Daniel H Solomon Journal: Am J Epidemiol Date: 2007-05-15 Impact factor: 4.897
Authors: Huong Q McLean; Brian D W Chow; Jeffrey J VanWormer; Jennifer P King; Edward A Belongia Journal: J Infect Dis Date: 2016-07-28 Impact factor: 5.226
Authors: Thorunn A Olafsdottir; Kristjan F Alexandersson; Gardar Sveinbjornsson; Giulia Lapini; Laura Palladino; Emanuele Montomoli; Giuseppe Del Giudice; Daniel F Gudbjartsson; Ingileif Jonsdottir Journal: Front Immunol Date: 2018-01-08 Impact factor: 7.561
Authors: M Teresa Aguado; Jane Barratt; John R Beard; Bonnie B Blomberg; Wilbur H Chen; Julian Hickling; Terri B Hyde; Mark Jit; Rebecca Jones; Gregory A Poland; Martin Friede; Justin R Ortiz Journal: Vaccine Date: 2018-01-12 Impact factor: 3.641
Authors: Min-Chul Kim; Sung-Cheol Yun; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim Journal: PLoS One Date: 2018-06-14 Impact factor: 3.240
Authors: Divyansh Agarwal; Kenneth E Schmader; Andrew V Kossenkov; Susan Doyle; Raj Kurupati; Hildegund C J Ertl Journal: Immun Ageing Date: 2018-08-31 Impact factor: 6.400
Authors: Fiona P Havers; Jessie R Chung; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Joshua G Petrie; Alicia M Fry; Brendan Flannery Journal: Clin Infect Dis Date: 2019-05-02 Impact factor: 20.999